Keith T. Flaherty's Net Worth
$13.7 Million
Who is Keith T. Flaherty?
Keith T. Flaherty has an estimated net worth of $13.7 Million. This is based on reported shares across multiple companies, which include Kinnate Biopharma Inc., Clovis Oncology, Inc., Loxo Oncology, Inc., and Checkmate Pharmaceuticals, Inc..
SEC CIK
Keith T. Flaherty's CIK is 0001579310
Past Insider Trading and Trends
2018 was Keith T. Flaherty's most active year for acquiring shares with 4 total transactions. Keith T. Flaherty's most active month to acquire stocks was the month of May. 2019 was Keith T. Flaherty's most active year for disposing of shares, totalling 11 transactions. Keith T. Flaherty's most active month to dispose stocks was the month of January. 2018 saw Keith T. Flaherty paying a total of $59,200.00 for 76,020 shares, this is the most they've acquired in one year. In 2019 Keith T. Flaherty cashed out on 208,155 shares for a total of $48,916,425.00, their largest year based on trade value.
Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!
Kinnate Biopharma Inc. (KNTE) Snapshot price: $2.36
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| -100.00% | -66.38K |
—
|
—
|
0
|
Apr 3
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 12
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 13
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 11
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
Clovis Oncology, Inc. No price found
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 10
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 4
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 6
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Oct 11
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 8
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 9
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 11
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 12
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 13
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
Loxo Oncology, Inc. No price found
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| -100.00% | -9.73K |
$235.00 | -$2,287,020.00 |
0
|
Feb 15
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 13
| |||
Form 4
|
—
|
0
|
$87.36 | -$8,617,827.04 | 9.73K |
Jun 7
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jan 4
| |||
Form 4
| -42.69% | -7.25K |
$75.99 | -$550,921.46 | 9.73K |
Scheduled
|
Nov 20
| ||
Form 4
| -29.92% | -7.25K |
$72.26 | -$523,883.28 | 16.98K |
Scheduled
|
Aug 21
| ||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 22
| |||
Form 4
| -23.03% | -7.25K |
$45.09 | -$326,936.28 | 24.23K |
Scheduled
|
May 22
| ||
Form 4
| -18.72% | -7.25K |
$41.45 | -$300,516.85 | 31.48K |
Scheduled
|
Feb 21
| ||
Form 4
| -15.77% | -7.25K |
$30.23 | -$219,167.50 | 38.73K |
Scheduled
|
Dec 19
| ||
Form 4
| -23.97% | -14.50K |
$30.00 | -$435,000.00 | 45.98K |
Scheduled
|
Sep 7
| ||
Form 4
| -19.87% | -15.00K |
$26.00 | -$389,967.00 | 60.48K |
Scheduled
|
Aug 11
| ||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 10
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jul 28
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Dec 19
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jul 31
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
Checkmate Pharmaceuticals, Inc. No price found
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
|
—
|
0
|
—
|
—
|
0
|
May 31
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 16
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||